

Date: 12th August, 2025

To,
The Manager,
Department of Corporate Services,
BSE Limited
1st Floor, Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001
Scrip Code: 506235

To,
The Manager,
Listing Department,
National Stock Exchange of India Limited
"Exchange Plaza"
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Symbol: ALEMBICLTD

Dear Sir,

Sub: Outcome of Board Meeting

With reference to the captioned subject, the exchanges are hereby informed that the Board of Directors of Alembic Limited at its meeting held today has *inter alia* approved and took note of the following:

1) Unaudited Financial Results of the Company for the quarter ended 30th June, 2025.

In this connection, we enclose herewith the following:

- a) Consolidated Unaudited Financial Results for the quarter ended 30th June, 2025.
- b) Standalone Unaudited Financial Results for the quarter ended 30th June, 2025.
- c) Limited Review Report by Statutory Auditors on the Consolidated and Standalone Unaudited Financial Results.

2) Appointment of Mr. Udit Amin (DIN: 00244235), currently serving as Non-Executive Non-Independent Director, as Managing Director (KMP) of the Company for a period of 5 (five) years w.e.f. 1st October, 2025 subject to approval of members by way of a special resolution, Central Government and such other approval as may be required.

We hereby declare that Mr. Udit Amin is not debarred from holding the office of Managing Director by virtue of any SEBI order or any other such authority.

3) Resignation of Mrs. Malika Amin (DIN: 00242613) from the position of Managing Director & CEO of the Company w.e.f. 1st January, 2026. She will continue serving the Board as Non-Executive Director, liable to retire by rotation.



ALEMBIC LIMITED

The details as required under SEBI Listing Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 and copy of resignation letter from Mrs. Malika Amin are enclosed herewith as "Annexure – A" and "Annexure – B" respectively.

The time of commencement of the Board Meeting was 3:00 p.m. and the time of conclusion was 3:40 p.m.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,

For Alembic Limited


Keval Thakkar
Company Secretary





Encl.: A/a

Statement of Consolidated Unaudited Financial Results for the Quarter ended 30th June, 2025

Rs. in Lakhs

Sr. No	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from Operations	4,975	6,027	5,078	22,189
2	Other Income	359	296	196	7,489
3	Total Income	5,334	6,323	5,274	29,678
4	Expenses				
	Cost of Materials Consumed	345	192	286	800
	Cost of Construction	1,010	1,549	1,191	6,005
	Changes in Inventories of Finished Goods and WIP	174	(3)	131	111
	Employee Benefit Expenses	783	650	773	2,731
	Finance Costs	59	62	49	247
	Depreciation and amortisation expense	279	275	250	1,063
	Other Expenses	705	906	657	3,170
	Total Expenses	3,356	3,632	3,337	14,128
5	Profit Before Tax (3-4)	1,978	2,692	1,937	15,550
6	Tax Expenses				
	Current Tax	202	345	234	1,763
	Deferred Tax	(3)	128	(38)	(514)
	Short / (Excess) Provision of earlier years	-	(156)	-	(156)
7	Net Profit after tax for the Period	1,780	2,375	1,742	14,457
8	Share of Associate's Profit/(Loss)	4,384	4,470	3,840	16,610
9	Net Profit/(Loss) after tax and Share of Associate's Profit/(Loss)	6,164	6,845	5,582	31,068
10	Other Comprehensive Income				
	A (i) Items that will not be reclassified to Profit or (Loss)	482	(2,626)	4,348	(3,511)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(69)	388	(490)	(108)
	B (i) Items that will be reclassified to Profit or (Loss)	31	106	(3)	188
11	Total Comprehensive Income/(Loss) for the Period	6,609	4,713	9,436	27,636
12	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
13	Other Equity (excluding Revaluation Reserve)				2,04,790
14	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	2.40	2.67	2.17	12.10





Alembic Limited
Segment wise Consolidated Revenue and Results

Sr. No	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	Year Ended 31.03.2025 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,295	778	1,072	3,221
	b. Real Estate Business	3,680	5,248	4,006	18,967
	Total Income from Operations (Net)	4,975	6,027	5,078	22,189
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	273	188	50	473
	b. Real Estate Business	1,594	2,563	1,924	8,806
	Total	1,867	2,751	1,974	9,278
	Unallocable Income and Expenditure				
	(i) Interest Expense	(59)	(62)	(49)	(247)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	171	(12)	31	6,471
	(iii) Other Income / (Expense)	0	15	(20)	47
	Total Profit Before Tax	1,978	2,692	1,937	15,550
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	19,170	18,722	18,752	18,722
	b. Real Estate Business	46,822	44,313	39,663	44,313
	c. Unallocated	1,86,165	1,87,265	1,86,495	1,87,265
	Total	2,52,158	2,50,300	2,44,910	2,50,300
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,647	3,128	3,582	3,128
	b. Real Estate Business	10,857	9,947	8,987	9,947
	c. Unallocated	3,356	3,367	4,349	3,367
	Total	17,861	16,441	16,918	16,441

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024.




For Alembic Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 12th August, 2025

Statement of Standalone Unaudited Financial Results for the Quarter ended 30th June, 2025

Sr. No.	Particulars	Quarter Ended			Rs. in Lakhs
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Revenue from Operations	4,789	5,822	4,908	21,436
2	Other Income	346	278	189	7,451
3	Total Income	5,134	6,100	5,097	28,887
4	Expenses				
	Cost of Materials Consumed	345	192	286	800
	Cost of Construction	1,010	1,549	1,191	6,005
	Changes in Inventories of Finished Goods and WIP	174	(3)	131	111
	Employee Benefit Expenses	783	650	773	2,731
	Finance Costs	42	45	34	183
	Depreciation and amortisation expense	270	266	241	1,024
	Other Expenses	619	832	582	2,833
	Total Expenses	3,243	3,532	3,238	13,688
5	Profit Before Tax (3-4)	1,892	2,568	1,859	15,199
6	Tax Expenses				
	Current Tax	180	315	213	1,675
	Deferred Tax	(0)	126	(37)	(514)
	Short / (Excess) Provision of earlier years	-	(156)	-	(156)
7	Net Profit after tax for the Period	1,712	2,283	1,684	14,195
8	Other Comprehensive Income				
	(i) Items that will not be reclassified to Profit or (Loss)	495	(2,673)	4,459	(3,457)
	(ii) Income tax relating to items that will not be reclassified to Profit or (Loss)	(71)	383	(510)	(132)
9	Total Comprehensive Income/(Loss) for the Period	2,136	(7)	5,633	10,606
10	Paid up Equity Share Capital (Face Value of Rs 2/- per share)	5,135.64	5,135.64	5,135.64	5,135.64
11	Other Equity (excluding Revaluation Reserve)				56,250
12	Earnings per equity share (FV Rs. 2/- per share) Basic & Diluted (In Rs.)	0.67	0.89	0.66	5.53



Alembic Limited



Segment wise Standalone Revenue and Results

Rs. in Lakhs

Sr. No.	Particulars	Quarter Ended			Year Ended
		30.06.2025 (Unaudited)	31.03.2025 (Audited)	30.06.2024 (Unaudited)	31.03.2025 (Audited)
1	Segment Revenue				
	Revenue from Operations				
	a. Active Pharmaceutical Ingredients Business	1,295	778	1,072	3,221
	b. Real Estate Business	3,493	5,043	3,835	18,214
	Total Income from Operations (Net)	4,789	5,822	4,908	21,436
2	Segment Results (Profit (+)/ Loss (-) before Taxes and interest from each segment)				
	a. Active Pharmaceutical Ingredients Business	273	188	50	473
	b. Real Estate Business	1,490	2,423	1,831	8,390
	Total	1,763	2,611	1,881	8,863
	Unallocable Income and Expenditure				
	(i) Interest Expense	(42)	(45)	(34)	(183)
	(ii) Dividend Income and Gain/(Loss) on Fair Value Change of Financial Asset	171	(12)	31	6,471
	(iii) Other Income / (Expense)	0	15	(20)	47
	Total Profit Before Tax	1,892	2,568	1,859	15,199
3	Segment Assets				
	a. Active Pharmaceutical Ingredients Business	19,170	18,722	18,752	18,722
	b. Real Estate Business	45,574	43,080	38,784	43,080
	c. Unallocated	39,847	39,181	45,057	39,181
	Total	1,04,591	1,00,983	1,02,592	1,00,983
4	Segment Liabilities				
	a. Active Pharmaceutical Ingredients Business	3,647	3,128	3,582	3,128
	b. Real Estate Business	9,944	9,022	8,154	9,022
	c. Unallocated	3,545	3,514	4,347	3,514
	Total	17,136	15,664	16,084	15,664

Notes:

- The above results have been reviewed by Statutory Auditors, recommended by Audit Committee and approved by the Board of Directors of the Company.
- The previous quarter's / year's figures have been regrouped / rearranged wherever necessary to make it comparable with the current quarter / year.
- The figures for the quarter ended 31st March, 2025 are the balancing figures between the audited figures in respect of full financial year ended 31st March, 2025 and year to date unaudited figures upto third quarter ended 31st December, 2024.



For Alembic Limited

Chirayu Amin
Chairman

Place : Vadodara
Date : 12th August, 2025

Independent Auditor's Review Report on Unaudited Consolidated Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited


1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Alembic Limited ("the Parent") and its subsidiary (the Parent and its subsidiary together referred to as "the Group") for the quarter ended 30th June, 2025 ("the Statement") attached herewith, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the Securities Exchange Board of India under Regulation 33 (8) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, to the extent applicable.

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Consolidated Financial Statements for the year ended 31st March, 2025. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

5. The statement includes results of the following entities:

- i. Alembic City Limited (Subsidiary)
- ii. Alembic Pharmaceuticals Limited (Associate)

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

7. We did not review the financial result of a subsidiary included in the unaudited consolidated financial results, whose financial results reflect total revenue of Rs. 915.46 lakhs, total net profit after tax of Rs.7.47 lakhs and total comprehensive income of Rs. 7.58 lakhs for the quarter ended 30th June, 2025. The unaudited consolidated financial results also include the Group's share of net profit after tax of Rs. 4,384.48 lakhs and total comprehensive income of Rs. 4,404.74 lakhs for the quarter ended 30th June, 2025, as considered in the statement, in respect of an associate. These financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of a subsidiary and associate, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the unaudited consolidated quarterly financial results is not modified with respect of the above matter.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date: 12th August, 2025

UDIN: 25158289BMHZZU6022



Independent Auditor's Review Report on Unaudited Standalone Quarterly Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Alembic Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial results of **Alembic Limited** ("the Company") for the quarter ended 30th June, 2025 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34, ("Ind AS 34") "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



The Nirat, 3rd Floor, 18, Winward Business Park, Behind Emerald One Complex, In the lane of Dr. Prasant Buch's Hospital, Jetalpur, Vadodara 390 007. Tel: +91 265 234 3483

Website: www.cnkindia.com

VADODARA | MUMBAI | CHENNAI | AHMEDABAD | GIFT CITY | BENGALURU | DELHI | PUNE | DUBAI | ABU DHABI

4. Emphasis of Matter

We draw attention to the status of disputed liability related to pending electricity duty matter. During the previous periods, the Company had made aggregate provision towards total principal amount being Rs. 2,052.13 lakhs for the disputed matter(s) filed against State of Gujarat, Collector of Electricity Duty & others. The interest amount thereon is not ascertainable and is disclosed as contingent liability in the Standalone Financial Statements for the year ended 31st March, 2025. Further, the Company has deposited Rs. 35 Crores with the Hon'ble Supreme Court on 26th May, 2023 and the appeal filed by the Company has been admitted.

Our opinion is not modified in respect of above matter.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of Unaudited standalone financial results prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which, it is to be disclosed, or that it contains any material misstatement.

For C N K & Associates LLP

Chartered Accountants

Firm Registration No. 101961W/W-100036

Rachit Sheth

Rachit Sheth

Partner

Membership No.158289

Place: Vadodara

Date:12th August, 2025

UDIN: 25158289BMHZZT4605



Annexure – A

Details required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024:

Particulars	Details	
Name	Mr. Udit Amin (DIN: 00244235)	Mrs. Malika Amin (DIN: 00242613)
Reason for change	Appointment as Managing Director of the Company.	Resigned from the position of Managing Director & CEO and continue as Non-Executive Director of the Company liable to retire by rotation.
Date of appointment / Cessation (as applicable) and terms of appointment	1 st October, 2025 Term of Appointment: 5 years.	1 st January, 2026
Brief profile (in case of appointment)	Mr. Udit Amin graduated from University of Michigan, USA with Economics as main subject with focus on International trade. In his early career, he worked in regulatory department at Ivax, UK. He has extensive experience of over 22 years and has successfully led Business Operations and Strategic initiatives across the Real Estate, Specialty Chemicals, and Pharmaceutical industries.	Not Applicable
Disclosure of relationships between directors (in case of appointment of a director)	Mr. Udit Amin is son of Mr. Chirayu Amin, Chairman and Mrs. Malika Amin, Managing Director & CEO.	Not Applicable



ALEMBIC LIMITED

Malika Chirayu Amin

F10/195, Race Course Circle,
Gotri Road, Vadodara - 390 007
Email: malika@alembic.co.in

Date: 12th August, 2025

To,
The Board of Directors,
Alembic Limited
Alembic Road,
Vadodara-390 003,
Gujarat – India.

Subject: Resignation from the position of Managing Director & CEO of the Company

Dear Members of the Board,


With reference to the captioned subject, I hereby tender my resignation from the position of Managing Director & CEO of the Company w.e.f. 1st January, 2026. If the Board of the Company so wishes, I would be glad to continue serving on the Board in the capacity of a rotational Non-Executive Director.

I express my sincere appreciation to the Board Members for providing support during my tenure as Managing Director & CEO the Company.

Kindly acknowledge the receipt of this letter and initiate the necessary formalities.

Thanking You,

Yours Faithfully,



Malika Chirayu Amin
DIN: 00242613